Outcome of recurrent and metastatic small cell carcinoma of the bladder

Ismaili, Nabil; Heudel, Pierre; Elkarak, Fadi; Kaikani, Wafaa; Bajard, Agathe; Ismaili, M.; Errihani, Hassan; Droz, Jean Pierre; Fléchon, Aude

doi:10.1186/1471-2490-9-4

Cited by 46 publications

(42 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, about 50% of primary urinary SMCCs are associated with urothelial carcinoma (in situ or invasive) or other nonurothelial carcinomas of the bladder (e.g. adenocarcinoma, squamous cell carcinoma) [6,7,8,9]. Therefore, the presence of a non-small cell component should not negate the diagnosis of SMCC.…”

Section: Discussionmentioning

confidence: 99%

Small Cell Carcinoma of the Ovary Presenting in a Urine Cytology Specimen: A Case Report

et al. 2011

View full text Add to dashboard Cite

Background: Small cell carcinoma (SMCC) is rarely diagnosed in urine specimens. Cytologically, this tumor is similar to pulmonary SMCC. However, clinicopathologic correlation may be required to differentiate between primary urinary bladder SMCC and metastatic SMCC from a remote primary or secondary bladder involvement by direct extension of the tumor from nearby organs (prostate, uterus, or ovary). A unique case of a rare pulmonary-type ovarian SMCC, the tumor cells of which were detected in a voided urine specimen, is described herein. Case: A 79-year-old female presented to the urologic clinic with a history of metastatic SMCC of unknown primary with hematuria. The voided urine specimen examination revealed tumor cells cytomorphologically consistent with small cell neuroendocrine carcinoma. Following cytologic diagnosis, cystoscopic examination and bladder biopsy were performed. The histopathology revealed a widely invasive tumor with a morphology typical of SMCC. The overlying urothelium was unremarkable. By immunohistochemistry, tumor cells were found positive for neuroendocrine markers, EMA and WT-1. The morphologic and immunohistochemical features of the tumor were most consistent with urinary bladder involvement by pulmonary-type primary ovarian SMCC. Conclusion: It is justified to think that SMCC cell detection in urine specimens does not necessarily imply their origin from primary bladder malignancy. Performing additional studies may be prudent in order to exclude secondary involvement of the bladder in this tumor as the correct diagnosis has significant clinical implications.

show abstract

Section: Discussionmentioning

confidence: 99%

Small Cell Carcinoma of the Ovary Presenting in a Urine Cytology Specimen: A Case Report

et al. 2011

View full text Add to dashboard Cite

show abstract

“…It has been found that pure small cell carcinoma tends to have a poorer outcome than mixed small cell carcinoma bladder. 18 Immunohistochemical markers commonly used to demonstrate neuroendocrine differentiation. These markers are neuron specific enolase (NSE), chromogranin A (CGA), synaptophysin, cytokeratin, TTF1.…”

Section: 7mentioning

confidence: 99%

Rare Presentation of Small Cell Neuroendocrine Carcinoma of Urinary Bladder

Chaudhary¹,

Pathology²

2018

jmscr

View full text Add to dashboard Cite

show abstract

“…In metastatic SCCUB the presence of brain metastasis is less frequently reported, even though described in16% of patients 10,23,24 .…”

Section: Patients With Brain Metastasis or Relapsementioning

confidence: 99%

Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma

Macedo¹,

Ribeiro²,

Curigliano³

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Small cell carcinoma of the urinary bladder (SCCUB) is considered to be a tumor with a neuroendocrine phenotype characterised by aggressive behaviour and poor prognosis. Small cell carcinoma of the urinary bladder comprises 0,35 to 1% of all bladder cancers and is frequently observed in combination with other histological subtypes of carcinoma. Clinical presentation is characterized by advanced stage at diagnosis and rapidly progressive disease. In daily clinical practice there is no gold standard for the management of patients affected by this disease. Treatment of patients with limited disease combines neoadjuvant platinum-based chemotherapy followed by specific local treatment of the primary tumour. Cystectomy or radiotherapy should be proposed on an individual basis. In the metastatic setting, prognosis remains poor with a potential benefit from chemotherapy containing platinum compounds. Treatment of small cell carcinoma of the urinary bladder is based on evidence obtained from case reports and retrospective analyses. Due to low disease frequency there is a lack of randomized trials to provide guidance as to optimal therapy. Thus, systemic and local approaches are extrapolated from the literature available for the treatment of small cell carcinomas at other (nonurological) sites. We provide an overview of the currently available literature with it's main focus on the treatment of either locally advanced or metastatic small cell carcinoma of the urinary bladder.

show abstract

Outcome of recurrent and metastatic small cell carcinoma of the bladder

Abstract: Background: Bladder small cell carcinoma is an uncommon tumour. Through a retrospective study we will present the evolution of recurrent and metastatic disease and outcome of patients treated at Léon-Bérard Cancer Centre.

Cited by 46 publications

References 31 publications

Small Cell Carcinoma of the Ovary Presenting in a Urine Cytology Specimen: A Case Report

Small Cell Carcinoma of the Ovary Presenting in a Urine Cytology Specimen: A Case Report

Rare Presentation of Small Cell Neuroendocrine Carcinoma of Urinary Bladder

Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma

Contact Info

Product

Resources

About